American Journal of Clinical Pathology · 2016 · 30 citations · 18 references
MedicineOncologyPathologyMetastasisMolecular OncologyNeoplasiaGastrointestinal NeoplasmsGastrointestinal Stromal TumorsMalignant NeoplasmsMalignant TumorsMetastatic Gastrointestinal CancerTumor HistopathologyAtypical CellsGastrointestinal MalignancyGastrointestinal TumorsGenetic Mutation FrequencyLoss-of-function MutationsMetastatic Gastrointestinal Stromal TumorsParallel SequencingRb1 Alterations
OBJECTIVES: Loss-of-function mutations in TP53 and CDKN2A have been found at varying frequencies in gastrointestinal stromal tumors (GISTs), while no mutations of RB1 have been reported to date. The aim of the current study was to determine the mutation frequency of TP53, RB1, and CDKN2A in GISTs. METHODS: A cohort of 83 primary untreated GISTs was analyzed for mutations in TP53, RB1, and CDKN2A by massive parallel sequencing. Tumors with mutations in TP53 and RB1 were analyzed by fluorescence in situ hybridization for the corresponding gene loci. RESULTS: Two GISTs harbored inactivating mutations in RB1, and two other GISTs displayed inactivating mutations in TP53 All four tumors were KIT mutant high-risk tumors with highly cellular sarcomatous histomorphology and variable combinations of plump spindle cells to epithelioid highly atypical cells and high mitotic activity. Three of these patients developed recurrent or metastatic disease, while the fourth patient showed tumor rupture intraoperatively. The combined overall frequency of TP53 and RB1 mutations was 13% considering high-risk or malignant GISTs. CONCLUSIONS: TP53 and RB1 mutations seem to be restricted to high-risk/malignant GISTs and occur at an equal although relatively low frequency.
18
Inactivation of the p53 pathway in retinoblastoma
Nikia A. Laurie, Stacy L. Donovan, Chie‐Schin Shih et al. · Nature · 2006 · 587 citations
Johanna C. Andersson‐Assarsson, Helene Sjögren, Jeanne M. Meis‐Kindblom et al. · American Journal Of Pathology · 2002 · 120 citations · Full text